Veracyte (VCYT)

• Market cap: $2.3B
• 1 day: -0.44%
• 5 days: -12.14%
• 1 month: -12.04%
• 3 months: -27.00%
• 6 months: -10.90%
• Year to date: -27.00%
• 1 year: 36.41%
• 5 years: 45.56%
• 10 years: 288.93%
• Sector: Healthcare
• Industry: Medical Laboratories

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,042% more call options, than puts

Call options by funds: $8.4M | Put options by funds: $736K

116% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 25

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

16% more capital invested

Capital invested by funds: $2.79B [Q3] → $3.25B (+$460M) [Q4]

8% more funds holding

Funds holding: 290 [Q3] → 314 (+24) [Q4]

0.08% more ownership

Funds ownership: 107.2% [Q3] → 107.27% (+0.08%) [Q4]

15% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 120

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 52% upside
• Avg. target: $47 59% upside
• High target: $51 73% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Stephens & Co. Mason Carrico 18% 1-year accuracy 5 / 28 met price target	52% upside $45	Overweight Reiterated	26 Mar 2025
Craig-Hallum John Wilkin 0% 1-year accuracy 0 / 3 met price target	52% upside $45	Buy Initiated	20 Mar 2025
UBS Lu Li 0% 1-year accuracy 0 / 3 met price target	66% upside $49	Buy Maintained	25 Feb 2025
Guggenheim Subbu Nambi 19% 1-year accuracy 3 / 16 met price target	52% upside $45	Buy Reiterated	25 Feb 2025
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target	73% upside $51	Buy Reiterated	25 Feb 2025